Current options for drug delivery to the spinal cord

Expert Opinion on Drug Delivery

Volumn 10, Issue 3, 2013, Pages 385-396

  Rossi, Filippo ^a,b   Perale, Giuseppe ^a,b   Papa, Simonetta ^a   Forloni, Gianluigi ^a   Veglianese, Pietro ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b POLITECNICO DI MILANO   (Italy)

Author keywords

Biomaterials; Blood spinal cord barrier; Central nervous system; Hydrogels; Nanoparticles; Spinal cord

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BIOMATERIAL; BRADYKININ RECEPTOR; GABAPENTIN; IMIDAZOLINE DERIVATIVE; NANOCARRIER; NEUROPROTECTIVE AGENT; PREGABALIN; TIGHT JUNCTION PROTEIN;

BIOCOMPATIBILITY; BLOOD SPINAL CORD BARRIER; CATHETER; CATHETER INFECTION; CELL STRUCTURE; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ELECTROMAGNETIC RADIATION; ENDOCYTOSIS; FIRST PASS EFFECT; GLASS TRANSITION TEMPERATURE; GRANULOMA; HUMAN; HYDROGEL; INTRACELLULAR SPACE; INTRACRANIAL HYPERTENSION; INTRATHECAL DRUG ADMINISTRATION; LIPID PEROXIDATION; LIQUORRHEA; MACROPHAGE; MINIPUMP; MULTIPLE SCLEROSIS; MUSCLE SPASM; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OSMOTIC PRESSURE; PERMEABILITY BARRIER; REVIEW; SCLEROSIS; SPINAL CORD DISEASE; SPINAL CORD TUMOR; THERMAL INJURY;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MICROCIRCULATION; NANOPARTICLES; NEUROPROTECTIVE AGENTS; REGIONAL BLOOD FLOW; SPINAL CORD; SPINAL CORD DISEASES;

EID: 84873901699     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.751372     Document Type: Review

References (114)

1. Watson C, Paxinos G, Kayalioglu G. The spinal cord: a christopher and dana reeve foundation text and atlas. Academic press; London: 2009
2. Skyrme AD, Selmon GPF, Apthorp A. Common spinal disorders explained. Remedica; London: 2005
3. Miller RG. Amyotrophic lateral sclerosis. Demos Medical Publishing; New York: 2010
4. Morren JA, Galvez-Jimenez N. Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. Expert Opin Investig Drugs 2012;21:297-320
5. Rabchevsky AG, Patel SP, Springer JE. Pharmacological interventions for spinal cord injury: where do we stand? How might we step forward? Pharmacol Ther 2011;132:15-29
6. Berry JD, Cudkowicz ME. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig (Lond) 2011;1:1375-89
7. Hawryluk GW, Rowland J, Kwon BK, et al. Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus 2008;25:E14
8. Bartanusz V, Jezova D, Alajajian B, et al. The blood-spinal cord barrier: morphology and clinical implications. Ann Neurol 2011;70:194-206
9. Cardoso FL, Brites D, Brito MA. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev 2010;64:328-63
10. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010;37:48-57
11. Bernacki J, Dobrowolska A, Nierwinska K, et al. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 2008;60:600-22
12. Ahn SH, Park HW, Lee BS, et al. Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms. Spine (Phila Pa 1976) 2003;28:341-6; discussion 46-7
13. Rintala DH, Holmes SA, Courtade D, et al. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil 2007;88:1547-60 (Pubitemid 350151394)
14. Kilpatrick GJ, Smith TW. Morphine-6- glucuronide: actions and mechanisms. Med Res Rev 2005;25:521-44
15. Bernard JM, Kick O, Bonnet F. Comparison of intravenous and epidural clonidine for postoperative patient-controlled analgesia. Anesth Analg 1995;81:706-12
16. Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage 2003;26:668-77 (Pubitemid 36802290)
17. Satoh M, Minami M. Molecular pharmacology of the opioid receptors. Pharmacol Ther 1995;68:343-64 (Pubitemid 26020722)
18. Kheder A, Nair KP. Spasticity: pathophysiology, evaluation and management. Pract Neurol 2012;12:289-98
19. Brennan PM, Whittle IR. Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. Br J Neurosurg 2008;22:508-19
20. Richard I, Menei P. Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders. Acta Neurochir Suppl 2007;97:213-18
21. Mullarkey T. Considerations in the treatment of spasticity with intrathecal baclofen. Am J Health Syst Pharm 2009;66:S14-22
22. Fenstermacher J, Gazendam J. Intra-arterial infusions of drugs and hyperosmotic solutions as ways of enhancing CNS chemotherapy. Cancer Treat Rep 1981;65(Suppl 2):27-37 (Pubitemid 13246905)
23. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012;32:1959-72
24. Wang M, Etu J, Joshi S. Enhanced disruption of the blood brain barrier by intracarotid mannitol injection during transient cerebral hypoperfusion in rabbits. J Neurosurg Anesthesiol 2007;19:249-56 (Pubitemid 47480717)
25. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000;20:217-30 (Pubitemid 30091457)
26. Erdlenbruch B, Schinkhof C, Kugler W, et al. Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain. Br J Pharmacol 2003;139:685-94 (Pubitemid 36819595)
27. Emerich DF, Dean RL, Osborn C, et al. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation. Clin Pharmacokinet 2001;40:105-23 (Pubitemid 32242793)
28. Hynynen K. Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev 2008;60:1209-17
29. Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron 2002;36:555-8 (Pubitemid 35346750)
30. Pardridge WM. Brain drug targeting and gene technologies. Jpn J Pharmacol 2001;87:97-103
31. Garzon-Aburbeh A, Poupaert JH, Claesen M, et al. A lymphotropic prodrug of L-dopa: synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3- dihexadecanoyl-2-[(S)-2-amino-3-(3,4- dihydroxyphenyl)prop anoyl] propane-1,2,3-triol. J Med Chem 1986;29:687-91 (Pubitemid 16034677)
32. Prokai L, Prokai-Tatrai K, Bodor N. Targeting drugs to the brain by redox chemical delivery systems. Med Res Rev 2000;20:367-416
33. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 2001;46:247-79
34. Nonaka N, Farr SA, Kageyama H, et al. Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins. J Pharmacol Exp Ther 2008;325:513-19 (Pubitemid 351574811)
35. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003;3:90-105
36. Zhang Y, Pardridge WM. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther 2005;313:1075-81 (Pubitemid 40727011)
37. Coloma MJ, Lee HJ, Kurihara A, et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 2000;17:266-74 (Pubitemid 30225129)
38. Kounnas MZ, Moir RD, Rebeck GW, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995;82:331-40
39. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004;104:29-45 (Pubitemid 39410561)
40. Liu Y, Wang CY, Kong XH, et al. Novel multifunctional polyethylene glycoltransactivating- transduction protein-modified liposomes cross the blood-barrier after spinal cord spinal cord injury. J Drug Target 2010;18:420-9
41. Wang H, Zhang S, Liao Z, et al. PEGlated magnetic polymeric liposome anchored with TAT for delivery of drugs across the blood-spinal cord barrier. Biomaterials 2010;31:6589-96
42. Reukov V, Maximov V, Vertegel A. Proteins conjugated to poly(butyl cyanoacrylate) nanoparticles as potential neuroprotective agent. Biotechnol Bioeng 2011;108:243-52
43. Cho Y, Shi R, Borgens RB, et al. Repairing the damaged spinal cord and brain with nanomedicine. Small 2008;4:1676-81
44. Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng 2007;96:203-9 (Pubitemid 46232255)
45. Mastropietro DJ, Omidian H, Park K. Drug delivery applications for superporous hydrogels. Expert Opin Drug Deliv 2012;9:71-89
46. Mout R, Moyano DF, Rana S, et al. Surface functionalization of nanoparticles for nanomedicine. Chem Soc Rev 2012;41:2539-44
47. Jiang W, Kim BYS, Rutka J, et al. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008;3:145-50 (Pubitemid 351355131)
48. Yu Y, Ferrari R, Lattuada M, et al. PLA-based nanoparticles with tunable hydrophobicity and degradation kinetics. J Polym Sci Polym Chem 2012;50:5191-200
49. Yoo JW, Mitragotri S. Polymer particles that switch shape in response to a stimulus. Proc Natl Acad Sci USA 2010;107:11205-10
50. Cerqueira SR, Silva BL, Oliveira JM, et al. Multifunctionalized CMCht/ PAMAM dendrimer nanoparticles modulate the cellular uptake by astrocytes and oligodendrocytes in primary cultures of glial cells. Macromol Biosci 2012;12:591-7
51. Wang YC, Wu YT, Huang HY, et al. Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury. Biomaterials 2008;29:4546-53
52. Lunov O, Syrovets T, Loos C, et al. Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. ACS Nano 2011;5:1657-69
53. Cho Y, Shi R, Ivanisevic A, et al. Functional silica nanoparticle- mediated neuronal membrane sealing following traumatic spinal cord injury. J Neurosci Res 2010;88:1433-44
54. Kim YT, Caldwell JM, Bellamkonda RV. Nanoparticle-mediated local delivery of methylprednisolone after spinal cord injury. Biomaterials 2009;30:2582-90
55. Takenaga M, Ishihara T, Ohta Y, et al. Nano PGE1 promoted the recovery from spinal cord injury-induced motor dysfunction through its accumulation and sustained release. J Control Release 2010;148:249-54
56. Menon PK, Muresanu DF, Sharma A, et al. Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in following intoxication of engineered nanoparticles from metals. CNS Neurol Disord Drug Targets 2012;11:40-9
57. Baumann MD, Kang CE, Tator CH, et al. Intrathecal delivery of a polymeric nanocomposite hydrogel after spinal cord injury. Biomaterials 2010;31:7631-9
58. Chvatal SA, Kim YT, Bratt-Leal AM, et al. Spatial distribution and acute anti-inflammatory effects of Methylprednisolone after sustained local delivery to the contused spinal cord. Biomaterials 2008;29:1967-75
59. Kim H, Tator CH, Shoichet MS. Chitosan implants in the rat spinal cord: biocompatibility and biodegradation. J Biomed Mater Res A 2011;97A:395-404
60. Stanwick JC, Baumann MD, Shoichet MS. In vitro sustained release of bioactive anti-NogoA, a molecule in clinical development for treatment of spinal cord injury. Int J Pharm 2012;426:284-90
61. Stanwick JC, Baumann MD, Shoichet MS. Enhanced neurotrophin-3 bioactivity and release from a nanoparticle-loaded composite hydrogel. J Control Release 2012;160:666-75
62. Goraltchouk A, Scanga V, Morshead CM, et al. Incorporation of protein-eluting microspheres into biodegradable nerve guidance channels for controlled release. J Control Release 2006;110:400-7 (Pubitemid 41827494)
63. Piotrowicz A, Shoichet MS. Nerve guidance channels as drug delivery vehicles. Biomaterials 2006;27:2018-27 (Pubitemid 41759495)
64. Forloni G. Responsible nanotechnology development. J Nanopart Res 2012;14:1-17
65. Harbaugh RE, Saunders RL, Reeder RF. Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery 1988;23:693-8 (Pubitemid 19018768)
66. Simpson RK Jr. Mechanisms of action of intrathecal medications. Neurosurg Clin N Am 2003;14:353-64
67. Brill S, Gurman GM, Fisher A. A history of neuraxial administration of local analgesics and opioids. Eur J Anaesthesiol 2003;20:682-9 (Pubitemid 37047742)
68. Lawson EF, Wallace MS. Advances in intrathecal drug delivery. Curr Opin Anaesthesiol 2012;25:572-6
69. Smith HS, Deer TR, Staats PS, et al. Intrathecal drug delivery. Pain Physician 2008;11:S89-S104 (Pubitemid 351682080)
70. Pardridge WM. Drug delivery to the brain. J Cereb Blood Flow Metab 1997;17:713-31 (Pubitemid 27427575)
71. Hayek SM, Deer TR, Pope JE, et al. Intrathecal therapy for cancer and non-cancer pain. Pain Physician 2011;14:219-48
72. Erwin A, Gudesblatt M, Bethoux F, et al. Intrathecal baclofen in multiple sclerosis: too little, too late? Mult Scler 2011;17:623-9
73. Belverud S, Mogilner A, Schulder M. Intrathecal pumps. Neurotherapeutics 2008;5:114-22 (Pubitemid 350299303)
74. Ghafoor VL, Epshteyn M, Carlson GH, et al. Intrathecal drug therapy for long-term pain management. Am J Health Syst Pharm 2007;64:2447-61 (Pubitemid 350209833)
75. Cohen SP, Dragovich A. Intrathecal analgesia. Anesthesiol Clin 2007;25:863-82; viii (Pubitemid 350186148)
76. Baumann MD, Kang CE, Stanwick JC, et al. An injectable drug delivery platform for sustained combination therapy. J Control Release 2009;138:205-13
77. Perale G, Rossi F, Santoro M, et al. Multiple drug delivery hydrogel system for spinal cord injury repair strategies. J Control Release 2012;159:271-80
78. Slaughter BV, Khurshid SS, Fisher OZ, et al. Hydrogels in regenerative medicine. Adv Mater 2009;21:3307-29
79. Perale G, Rossi F, Sundstrom E, et al. Hydrogels in spinal cord injury repair strategies. ACS Chem Neurosci 2011;2:366-45
80. Lee H, McKeon RJ, Bellamkonda RV. Sustained delivery of thermostabilized chABC enhances axonal sprouting and functional recovery after spinal cord injury. Proc Natl Acad Sci USA 2010;107:3340-5
81. Mokarram N, Merchant A, Mukhatyar V, et al. Effect of modulating macrophage phenotype on peripheral nerve repair. Biomaterials 2012;33:8793-801
82. Kubinova S, Horak D, Plichta Z, et al. Highly superporous cholesterol-modified poly(2-hydroxyethyl methacrylate) scaffolds for spinal cord injury repair. J Biomed Mater Res A 2011;99A:618-29
83. Shoichet MS. Polymer scaffolds for biomaterials applications. Macromolecules 2010;43:581-91
84. Amoozgar Z, Rickett T, Park J, et al. Semi-interpenetrating network of polyethylene glycol and photocrosslinkable chitosan as an in-situ forming nerve adhesive. Acta Biomater 2012;8:1849-58
85. Jain A, Kim YT, McKeon RJ, et al. In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials 2006;27:497-504 (Pubitemid 41457252)
86. Schaub NJ, Gilbert RJ. Controlled release of 6-aminonicotinamide from aligned, electrospun fibers alters astrocyte metabolism and dorsal root ganglia neurite outgrowth. J Neural Eng 2011;8:1-10
87. Yang CY, Song B, Ao Y, et al. Biocompatibility of amphiphilic diblock copolypeptide hydrogels in the central nervous system. Biomaterials 2009;30:2881-98
88. Wang Y, Lapitsky Y, Kang CE, et al. Accelerated release of a sparingly soluble drug from an injectable hyaluronan-methylcellulose hydrogel. J Control Release 2009;140:218-23
89. Pritchard CD, O'Shea TM, Siegwart DJ, et al. An injectable thiol-acrylate poly (ethylene glycol) hydrogel for sustained release of methylprednisolone sodium succinate. Biomaterials 2011;32:587-97
90. Kang CE, Poon PC, Tator CH, et al. A new paradigm for local and sustained release of therapeutic molecules to the injured for neuroprotection and tissue repair. Tissue Eng A 2009;15:595-604
91. Zhu Y, Wang A, Shen W, et al. Nanofibrous patches for spinal cord regeneration. Adv Funct Mater 2010;20:1443-0
92. Varghese OP, Sun WL, Hilborn J, et al. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach. J Am Chem Soc 2009;131:8781-3
93. Anderson SB, Lin CC, Kuntzler DV, et al. The performance of human mesenchymal stem cells encapsulated in cell-degradable polymer-peptide hydrogels. Biomaterials 2011;32:3564-74
94. Kubinova S, Horak D, Kozubenko N, et al. The use of superporous Ac- CGGASIKVAVS-OH-modified PHEMA scaffolds to promote cell adhesion and the differentiation of human fetal neural precursors. Biomaterials 2010;31:5966-75
95. Macaya D, Ng KK, Spector M. Injectable collagen-genipin gel for the treatment of spinal cord injury: in vitro studies. Adv Funct Mater 2011;21:4788-97
96. Vulic K, Shoichet MS. Tunable growth factor delivery from injectable hydrogels for tissue engineering. J Am Chem Soc 2012;134:882-5
97. von Burkersroda F, Schedl L, Gopferich A. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 2002;23:4221-31 (Pubitemid 34814991)
98. Muresanu DF, Sharma A, Tian ZR, et al. Nanowired of antioxidant compound H-290/51 enhances neuroprotection in hyperthermia-induced neurotoxicity. CNS Neurol Disord Drug Targets 2012;11:50-64
99. Sharma HS. Early microvascular reactions and blood-spinal cord barrier disruption are instrumental in pathophysiology of spinal cord injury and repair: novel therapeutic strategies including nanowired drug delivery to enhance neuroprotectio. J Neural Transm 2011;118:155-76
100. Sharma HS, Ali SF, Dong W, et al. Drug delivery to the spinalcord tagged with nanowire enhances neuroprotective efficacy and functional recovery following trauma to the rat spinal cord. Ann NY Acad Sci 2007;1122:197-218 (Pubitemid 350249549)
101. Tian ZR, Sharma A, Nozari A, et al. Nanowired to enhance neuroprotection in drug delivery spinal cord injury. CNS Neurol Disord Drug Targets 2012;11:86-95
102. Kwon BK, Okon E, Hillyer J, et al. A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury. J Neurotrauma 2011;28:1545-88
103. Kwon BK, Okon EB, Plunet W, et al. A systematic review of directly applied biologic therapies for acute spinal cord injury. J Neurotrauma 2011;28:1589-610
104. Tetzlaff W, Okon EB, Karimi-Abdolrezaee S, et al. A systematic review of cellular transplantation therapies for spinal cord injury. J Neurotrauma 2011;28:1611-82
105. Hyatt AJT, Wang D, Kwok JC, et al. Controlled release of chondroitinase ABC from fibrin gel reduces the level of inhibitory glycosaminoglycan chains in lesioned spinal cord. J Control Release 2010;147:24-9
106. Rossi F, Veglianese P, Santoro M, et al. Sustained delivery of chondroitinase ABC from hydrogel system. J Funct Biomater 2012;3:199-208
107. Koutsopoulos S, Unsworth LD, Nagai Y, et al. Controlled release of functional proteins through designer self-assembling peptide nanofiber hydrogel scaffold. Proc Natl Acad Sci USA 2009;106:4623-8
108. Liu T, Xu J, Chan B, et al. Sustained release of neurotrophin-3 and chondroitinase ABC from electrospun collagen nanofiber scaffold for spinal cord injury repair. J Biomed Mater Res A 2011;100A:236-42
109. Han QQ, Sun WJ, Lin H, et al. Linear ordered collagen scaffolds loaded with collagen-binding brain-derived neurotrophic factor improve the recovery of spinal cord injury in rats. Tissue Eng A 2009;15:2927-35
110. Liang W, Han Q, Jin W, et al. The promotion of neurological recovery in the rat spinal cord crushed injury model by collagen-binding BDNF. Biomaterials 2010;31:8634-41
111. Mehotra S, Lynam D, Maloney R, et al. Time controlled protein release from layer-by-layer assembled multilayer functionalized agarose hydrogels. Adv Funct Mater 2010;20:247-58
112. Stokols S, Tuszynski MH. Freeze-dried agarose scaffolds with uniaxial channels stimulate and guide linear axonal growth following spinal cord injury. Biomaterials 2006;27:443-51 (Pubitemid 41457247)
113. Burdick JA, Ward M, Liang E, et al. Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. Biomaterials 2006;27:452-9 (Pubitemid 41457248)
114. Hamann MCJ, Tator CH, Shoichet MS. Injectable intrathecal delivery system for localized administration of EGF and FGF-2 to the injured rat spinal cord. Exp Neurol 2005;194:106-19 (Pubitemid 40719747)